NLS Pharmaceutics Names Prof. Tamir Ben-Hur to NewcelX Scientific Advisory Board
I'm PortAI, I can summarize articles.
NLS Pharmaceutics Ltd. has appointed Professor Tamir Ben-Hur, a prominent neurologist, to its Scientific Advisory Board for NewcelX. This follows the merger of Kadimastem Ltd.’s stem-cell platforms with NLS Pharmaceutics’ expertise in CNS therapeutics. NewcelX aims to develop innovative cell therapies for neurodegenerative diseases like ALS and diabetes, with Ben-Hur's appointment reinforcing the scientific vision of the new entity.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments